About US
Contact us
-
Shkreli charges prompt Nasdaq to delist KaloBiosMartin Shkrelihas already been ousted as CEO of KaloBios ($KBIO). And now, Nasdaq plans to delist the company, citing Shkreli's recent arrest on fraud and looting charges as one reason for the move.2015/12/24
-
What's the calendar bringing biopharma next year? Our top 5 ideasWinter days are short and dark. December is winding down. If you're not already on a holiday break, you likely will be soon. So, it's a good time to take a minute to think about what's ahead in the ne2015/12/24
-
Lyxumia's CV results may help Sanofi's case for approval, but they won't score it points against SGLT2sTheNew England Journal of Medicinehas laid out the data from a cardiovascular outcomes trial of Sanofi's ($SNY) GLP-1 diabetes hopefulLyxumia, and the good news for the French drugmaker is that the dr2015/12/4
-
Japan poised to put 70% price lid on biosimilars, cap generics at 50% of reference drugJapanis considering capping the price of biosimilars at 70% of the reference drug, while lowering the price cap on generics from 60% to 50% of the price for the drugs they copy. The government has pus2015/12/4
-
Can Pfizer finally orchestrate a winning megamerger after so many disappointments?Pfizer's ($PFE) decision to buy Allergan ($AGN) wasn't much of a surprise; the nominally Dublin-based Allergan was among the few buyout targets that could deliver CEOIan Read's desired tax inversion.2015/12/3
-
Novo touts SGLT2-topping data for blockbuster VictozaSGLT2 drugs may be in the diabetes spotlight thanks to recent data showing that one of them--Eli Lilly ($LLY) andBoehringer Ingelheim'sJardiance--could cut cardiovascular risks. But Novo Nordisk ($NVO2015/12/3
-
Sanofi's Praluent scores first place in line for UnitedHealth unit's PCSK9 patientsHere's one way to privilege a new drug over its rival without blocking one entirely: Make patients try your favored product first. That's what UnitedHealth's ($UNH) Oxford unit is doing with the two2015/12/2
-
Russia amps up spending on locally made meds to spur Big Pharma productionRussiahas a lot of purchasing muscle, but few local producers when it comes to pharmaceuticals, and so officials have cooked up a plan to lure more foreign pharma partners. The government will boost i2015/12/2
-
Sanofi execs working with Lazard on $12B animal health sale or spinoffJust a couple of weeks ago, Sanofi ($SNY) announced that it was mulling options for its animal health unit,Merial, which offered "limited synergies" with the rest of the company. Now, investment banke2015/12/1
-
Samsung ponies up $740M to create massive biologics production site in South KoreaSamsung BioLogics, which is partnered up on biologics projects with a who's who of Western drugmakers, moved its biosimilars effort forward significantly this month with an EU recommendation for a cop2015/12/1